This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
MannKind will be receiving upfront and milestone payments relating to the development, approval and commercialization of the products along with upfront and potential milestone payments of approximately $140 million in total. The company is also eligible to receive tiered royalties on the sale of these products.
As per the agreement, Colby will have exclusive worldwide rights for the development and commercialization of disease-specific antigen compounds and intra-lymph node delivery technologies from the MKC1106 active immunotherapy programs. MannKind is currently developing these programs to treat patients suffering from melanoma, prostate, hematological disorders and other cancers.
We remind investors that MannKind has already completed a phase I program on MKC1106-MT for human melanoma. The study successfully achieved its primary objectives.
We are positive on the deal. The partnership program will safeguard MannKind’s financial interests while furthering pipeline development.
Meanwhile, we expect investor focus to remain on MannKind’s lead pipeline candidate Afrezza. Afrezza is an inhaled insulin being developed for the treatment of type I (MKC-171 study) or type II (MKC-175 study) diabetes. In October this year, the company finished enrolling patients for both studies. MannKind believes that it can complete both trials in the second quarter of 2013 and submit a new drug application in the third quarter of 2013.
Currently, we have a Neutral recommendation on MannKind, which carries a Zacks #3 Rank (short-term Hold rating).
Please login to Zacks.com or register to post a comment.